Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

28 Sept 2023

Abstract excerpt

Drosophila melanogaster is a valuable model organism for a wide range of biological exploration. The well-known advantages of D. melanogaster include its relatively simple biology, the ease with which it is genetically modified, the relatively low financial and time costs associated with their short gestation and life cycles, and the large number of offspring they produce per generation. D. melanogaster has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Insect Resistance and Genetics
Share to Mosquito-borne diseases and control
Share to Neurobiology and Insect Physiology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37840914
DOI: 10.3389/fneur.2023.1271941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s diseasePMID 37840914Read ↗

Neuroprotective potential of an <i>Ayurvedic</i> compound “Ras-Sindoor” on <i>Drosophila melanogaster</i> model of Parkinson’s diseaseSemantic proximity Read ↗

Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseasesSemantic proximity Read ↗

Adult health and transition stage-specific rotenone-mediated Drosophila model of Parkinson’s disease: Impact on late-onset neurodegenerative disease modelsSemantic proximity Read ↗

Ameliorative Role of Nutraceuticals on Neurodegenerative Diseases Using theDrosophila melanogasteras a Discovery Model to Define BioefficacySemantic proximity Read ↗

Drosophila Models of Parkinson's Disease: Discovering Relevant Pathways and Novel Therapeutic StrategiesSemantic proximity Read ↗

Using Drosophila as a platform for drug discovery from natural products in Parkinson's diseaseSemantic proximity Read ↗

Systematic Review of Caenorhabditis elegans Models for Mechanism Research and Drug Discovery in Parkinson’s DiseaseSemantic proximity Read ↗

Drosophila as a model system for studying lifespan and neuroprotective activities of plant-derived compoundsSemantic proximity Read ↗

Identification of structural features of selected flavonoids responsible for neuroprotection using a <i>Drosophila</i> model of Parkinson’s diseaseSemantic proximity Read ↗

Epicoccin A Ameliorates PD-Like Symptoms in Zebrafish: Enhancement of PINK1/Parkin-Dependent Mitophagy and Inhibition of Excessive Oxidative StressSemantic proximity Read ↗

Neuroprotective Effects of the Nutraceutical Dehydrozingerone and its C2- symmetric Dimer in a Drosophila Model of Parkinson’s DiseaseSemantic proximity Read ↗

GardeninA confers neuroprotection against environmental toxin in a Drosophila model of Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.